CoChat

Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial

Open access
Ibarra, Alvin, Latreille-Barbier, Mathilde, Donazzolo, Yves, Pelletier, Xavier, Ouwehand, Arthur C. · 2018 · Gut Microbes

The DOI matches its Crossref record, with a small difference in title or year; 54 of the 54 references it cites were found in a registry or an index.

Abstract

CFU of HN019/day for constipation. A total of 228 adults who were diagnosed with functional constipation according to the Rome III criteria were randomized in a double-blind and placebo-controlled trial. Colonic transit time (CTT), the primary outcome, and secondary outcomes that were measured using inventories-patient assessment of constipation symptoms (PAC-SYM) and quality of life (PAC-QoL), bowel function index (BFI), bowel movement frequency (BMF), stool consistency, degree of straining, bowel emptying, bloating, and pain severity-were assessed. Ancillary parameters and harms were also evaluated. There were no statistically significant differences in the primary or secondary outcomes between interventions. A post hoc analysis of 65 participants with fewer than 3 bowel movements per week (BMF ≤ 3/week) showed a physiologically relevant increase in weekly BMF in the high- (+2.0) and low-dose (+1.7) HN019 groups-by RMANOVA, the HN019 groups with BMF ≤ 3/week, pooled together, had a higher BMF versus placebo (P value = 0.01). Thus, improving low stool frequency could be a target of future interventions with HN019. High-dose HN019 also decreased the degree of straining at Day 28 versus placebo in those with BMF ≤ 3/week (P value = 0.02). Three unlikely related AEs-2 with low-dose HN019 and 1 with placebo-were followed until full recovery. In conclusion, although there were no differences in the primary analysis, HN019 is well tolerated and improves BMF in adults with low stool frequency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19490976.2017.1412908

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study setup. AEs, adverse events; BFI, bowel function index; ICF, informed consent form; IPAQ, International Physical Activity Questionnaire; PAC-SYM, Patient Assessment of Constipation Symptoms; PAC-QoL, Patient Assessment of Constipation Quality of Life. ■, radio-opaque markers were consumed at the study site from Day -6 to Day -1 during the run-in period and from Day 22 to Day 27 during the intervention period.
Figure 1. Study setup. AEs, adverse events; BFI, bowel function index; ICF, informed consent form; IPAQ, International Physical Activity Questionnaire; PAC-SYM, Patient Assessment of Constipation Symptoms; PAC-QoL, Patient Assessment of Constipation Quality of Life. ■, radio-opaque markers were consumed at the study site from Day -6 to Day -1 during the run-in period and from Day 22 to Day 27 during the intervention period.CC BY-NC-ND · PubMed Central
Figure 2. CONSORT diagram of the 28-day, 3-arm parallel-group (allocation ratio 1:1:1), double-blind, randomized, placebo-controlled, and monocenter study, preceded by a 2-week run-in period. BMF ≤ 3/week, participants from the ITT population who had fewer than or equal to 3 bowel movements per week during the entire 2-week run-in period; CONSORT, Consolidated Standards of Reporting Trials; ITT, intention-to-treat population—all participants randomized at the second visit who consumed at least 1 dose of the study product; PP, per-protocol population—participants who attended the end-of-study visit and received at least 80% of the assigned study product and consumed 100% of radio-opaque markers during the intervention on time.
Figure 2. CONSORT diagram of the 28-day, 3-arm parallel-group (allocation ratio 1:1:1), double-blind, randomized, placebo-controlled, and monocenter study, preceded by a 2-week run-in period. BMF ≤ 3/week, participants from the ITT population who had fewer than or equal to 3 bowel movements per week during the entire 2-week run-in period; CONSORT, Consolidated Standards of Reporting Trials; ITT, intention-to-treat population—all participants randomized at the second visit who consumed at least 1 dose of the study product; PP, per-protocol population—participants who attended the end-of-study visit and received at least 80% of the assigned study product and consumed 100% of radio-opaque markers during the intervention on time.CC BY-NC-ND · PubMed Central
Figure 3. Bowel movement frequency during the 28-day intervention in the BMF≤3/week population—participants from the ITT population who had fewer than or equal to 3 bowel movements per week during the entire 2-week run-in period. ▪, high-dose group (1 × 1010 CFU of HN019/day, n = 19); •, low-dose group (1 × 109 CFU of HN019/day, n = 23); and □, placebo group (n = 23). Values are mean ± SD. By RMANOVA, on pooling the high- and low-dose groups—the active groups—there was significant improvement in bowel movement frequency compared with the placebo group (P value = 0.01).
Figure 3. Bowel movement frequency during the 28-day intervention in the BMF≤3/week population—participants from the ITT population who had fewer than or equal to 3 bowel movements per week during the entire 2-week run-in period. ▪, high-dose group (1 × 1010 CFU of HN019/day, n = 19); •, low-dose group (1 × 109 CFU of HN019/day, n = 23); and □, placebo group (n = 23). Values are mean ± SD. By RMANOVA, on pooling the high- and low-dose groups—the active groups—there was significant improvement in bowel movement frequency compared with the placebo group (P value = 0.01).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 4

  1. WHO, Guidelines for ATC Classification, 1993, 23
  2. Miller LE, 2017, Annals of Gastroenterology, 30, 161
  3. Fateh R, 2010, Swiss medical weekly, 141, w13239
  4. Bian Z, 2013, Hong Kong medical journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine, 19, 44

Cited by

See all 125

Metadata

Authors
Ibarra, A., Latreille-Barbier, M., Donazzolo, Y., Pelletier, X., & Ouwehand, A. C.
Affiliations
  • DuPont (Finland) (FI)
  • Eurofins Optimed SAS, Clinical Research, Gières, France
  • Eurofins (France) (FR)
Corresponding author
Ibarra, Alvin
Venue
Gut Microbes
Published
2018-02-08
Volume
9
Issue
3
Pages
236-251
ISSN
  • 1949-0976 (ISSN-L)
  • 1949-0984
OpenAlex
W2773593508
Cited by
121
References
53
Citations by year
2026: 14 · 2025: 15 · 2024: 26 · 2023: 17 · 2022: 17 · 2021: 10 · 2020: 11 · 2019: 9 · 2018: 1
FWCI
6.32
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Gut Microbes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
DuPont
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
functional constipation, colonic transit time, probiotic supplementation, stool frequency, straining, stool consistency, quality of life, dose-ranging, adverse events
MeSH terms
Bifidobacterium animalis, Adolescent, Adult, Aged, Constipation, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Male, Middle Aged, Placebos, Quality of Life, Treatment Outcome, Probiotics, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. https://app.cochat.ai/papers/10.1080/19490976.2017.1412908
The paper
Ibarra, A., Latreille-Barbier, M., Donazzolo, Y., Pelletier, X., & Ouwehand, A. C. (2018). Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. https://doi.org/10.1080/19490976.2017.1412908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.